Poly-Unsaturated Fatty Acids in ADHD and in Other Neuropsychiatric Conditions: A Multiple Case Presentation
1Developmental Psychopathology Research Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy.
Insights
Poly-unsaturated fatty acids (PUFAs) show potential benefits for children with neurodevelopmental disorders. This case series explores integrating PUFA supplementation into pediatric practice for conditions like ADHD, especially when other treatments are unsuitable.
Area of Science:
- Pediatric Neurology
- Nutritional Neuroscience
Background:
- Neurodevelopmental disorders are prevalent in pediatric practice.
- A multi-professional approach is crucial for managing these conditions.
- Evidence suggests poly-unsaturated fatty acids (PUFAs) may offer benefits, yet practical guidelines are absent.
Observation:
- Four distinct pediatric cases illustrate the use of PUFA supplementation.
- Cases included children too young for ADHD medication, those with nonspecific neurodevelopmental disorders, and ADHD cases where parents refused medication or methylphenidate was insufficient.
Findings:
- PUFA supplementation was explored as an adjunct or alternative therapeutic strategy.
- The cases demonstrate potential integration of PUFAs into clinical management plans.
- This approach addresses specific challenges in treating pediatric neurodevelopmental conditions.
Implications:
- Highlights the potential role of PUFAs in pediatric neurodevelopmental disorder management.
- Suggests a need for further research and clinical guidelines on PUFA use.
- Offers practical insights for pediatricians managing common neurodevelopmental issues.
Abstract:
Neurodevelopmental disorders are seen quite commonly by general pediatricians. They should be managed with a multi-professional approach. The potential beneficial effect of poly-unsaturated fatty acids (PUFAs) has been reported in recent literature, but guidelines describing their use in everyday practice are still lacking. We describe four cases as examples of the possible integration of a supplementation with PUFAs in the management of four relatively common clinical situations (i.e., children too young to receive pharmacological treatment for ADHD, children with nonspecific neurodevelopmental disorders, children whose parents refuse consent for pharmacological treatment of ADHD, and children for whom methylphenidate is not sufficient to achieve expected results).
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
